All Perry Sternberg Articles
-
205Latest Myopia NewsFDA Advisory Committee to Meet on Sydnexis’ SYD-101
July 13, 2026 DEL MAR, Calif. — The U.S. Food and Drug Administration (FDA) shared that it will be convening an Advisory...
-
396Latest Myopia NewsSydnexis Shares Latest STAR Trial Data at AAPOS 2026
March 23, 2026 DEL MAR, Calif. — At the 2026 American Association for Pediatric Ophthalmology and Strabismus (AAPOS) annual meeting, Sydnexis shared...
-
1.4KLatest Myopia NewsSydnexis Partner Santen Wins U.K. Approval for Ryjunea to Slow Childhood Myopia
November 6, 2025 DEL MAR, Calif. — Sydnexis‘ partner Santen has announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA)...
-
641Latest Myopia NewsSydnexis Shares Pivotal Data from STAR Trial at AMCP Nexus
November 4, 2025 DEL MAR, Calif. — At the Academy of Managed Care Pharmacy (AMCP) Nexus 2025, Sydnexis shared topline results from...
-
807Latest Myopia NewsFDA Delays Approval of Sydnexis’ SYD-101 for Myopia, Asking for More Evidence
October 24, 2025 DEL MAR, Calif. — The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to...
-
979Latest Myopia News
Sydnexis Receives European Commission Approval of SYD-101
June 6, 2025 DEL MAR, Calif. — Sydnexis‘ proprietary low-dose atropine formulation, SYD-101, has received marketing authorization from the European Commission (EC)....
-
2.3KLatest Myopia News
Sydnexis Receives Positive Opinion in Europe for SYD-101
April 2, 2025 DEL MAR, Calif. — Sydnexis has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human...
-
1.8KLatest Myopia NewsFDA Accepts New Drug Application for Sydnexis’ SYD-101
March 11, 2025 DEL MAR, Calif. — The U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for...
-
1.4KClinicalWorking Toward an Approved Pharmacological Treatment for Myopia Management
sponsored content December 16, 2024 Privately held, clinical-stage pharmaceutical company, Sydnexis Inc. has recently completed an evaluation of its patented low-dose atropine...